AZD0837 + VKA INR 2-3
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Persistent or Permanent Nonvalvular Atrial Fibrillation
Conditions
Persistent or Permanent Nonvalvular Atrial Fibrillation
Trial Timeline
Oct 1, 2007 → May 1, 2009
NCT ID
NCT00645853About AZD0837 + VKA INR 2-3
AZD0837 + VKA INR 2-3 is a phase 2 stage product being developed by AstraZeneca for Persistent or Permanent Nonvalvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00645853. Target conditions include Persistent or Permanent Nonvalvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00645853 | Phase 2 | Completed |
Competing Products
20 competing products in Persistent or Permanent Nonvalvular Atrial Fibrillation